| Metric | Value ($ M) | Q2 FY25 | Q3 FY24 |
|---|---|---|---|
| Revenue | 1.4K | 2.9% | 1.1% |
| Total Income | 1.4K | 2.9% | 1.1% |
| Expenditure | 1.6K | 3.7% | 1.1% |
| PBT | -110.54 | 6.0% | 5.5% |
| Net Profit | -110.21 | 5.6% | 6.3% |
| OPM | -9.15% | 0.83pp | 0.06pp |
| NPM | -7.68% | 0.20pp | 0.43pp |
| EPS | — |
agilon health Reports Q3 2025 Results; Re-Establishes Full Year Outlook
04 May 2026 · 4 May, 8:14 am
Summary
agilon health announced its third quarter 2025 results, reporting a total revenue of $1.44 billion, a 1% decrease compared to the same period in 2024. The quarter was impacted by lower-than-expected risk adjustment revenue of $73 million and a $20 million negative impact from exited markets. The adjusted EBITDA loss was $91 million, an improvement from the $96 million loss in the third quarter of 2024. The company is focused on transformation initiatives, including reducing operating costs by an expected $30 million in 2026, to drive improved financial performance.
Key Highlights
- 1
Agilon health reported a total revenue of $1.44 billion in the third quarter of 2025, a decrease of 1% compared to $1.45 billion in the third quarter of 2024.
- 2
The company's third quarter 2025 results reflect the impact of lower-than-expected 2025 risk adjustment revenue of $73 million.
- 3
Adjusted EBITDA loss was $91 million in the third quarter 2025, compared to a loss of $96 million in the third quarter 2024.
- 4
Total members on the agilon platform decreased to 618,000 as of September 30, 2025, compared to September 30, 2024.
- 5
The company expects to reduce operating expenses by $30 million in 2026 through transformation initiatives.
- 6
Medical margin was negative $57 million during the third quarter 2025, compared to negative $58 million in the third quarter 2024.
Management Comments
Ronald A. Williams
“In the third quarter we made tangible progress executing on our transformation initiatives while continuing to absorb the impact of historical challenges. We have enhanced data visibility, instilled a greater financial discipline in our payor contracting processes, and reduced operating costs. We are building a more streamlined, agile, accountable, and performance-driven organization. These efforts are already delivering measurable impact—reducing operating expenses by an expected $30 million in 2026, and supporting strong performance expectations for our BOI, clinical, and quality initiatives, with additional potential from more favorable rates, contract economics and payer bids. We remain focused on driving improved and sustainable financial performance in a dynamic healthcare market.”
Informational and educational content only. Not investment advice.